The 2 analysts offering 12-month price forecasts for Acer Therapeutics Inc have a median target of 11.00, with a high estimate of 12.00 and a low estimate of 10.00. The median estimate represents a +436.59% increase from the last price of 2.05.
The current consensus among 2 polled investment analysts is to Buy stock in Acer Therapeutics Inc. This rating has held steady since January, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.25
Reporting Date Mar 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.